Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (386)	3/25/2013 10:01:35 AM
From: Arthur Radley	Respond to of 507

Hit $10.99 this morning for new 52 week high--but volume is low, low, low!

To: ghmm who wrote (386)	4/7/2013 2:06:10 PM
From: Arthur Radley	1 Recommendation Read Replies (1) \| Respond to of 507

Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype SAN FRANCISCO, April 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed as a potential treatment for multiple cancers. NKTR-214 targets the IL-2 receptor complex through selective receptor binding to the IL2Rß subtype. Activation of the IL2Rß subtype promotes tumor killing by the body's own immune system. "We are extremely encouraged by the dramatic efficacy observed with NKTR-214 treatment in an aggressive and resistant preclinical model of melanoma," said Stephen Doberstein, Ph.D., Senior Vice President and Chief Scientific Officer of Nektar Therapeutics. "NKTR-214 is specifically designed to harness the potent immunostimulatory effects of the IL-2 receptor complex while minimizing the immunosuppressive effects that have greatly limited the efficacy of the native IL-2 protein. Importantly, NKTR-214 represents the first application of our technology platform to target a receptor subtype in the tumor microenvironment while avoiding the unwanted effects from off-target receptor binding. NKTR-214 also has improved pharmacokinetics and enhanced tumor penetration which allow for a ten-fold reduction in overall dosing. We are excited about the potential of NKTR-214 to emerge as a powerful new immunotherapy in the fight against cancer."